NASDAQ$RPTX
Repare Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Repare Therapeutics reported Q2 2025 results with $0.25M revenue and a net loss of $16.7M.
Revenue was $250,000 from collaboration agreements; operating loss was $17.8M and net loss was $16.7M (EPS -$0.39). Cash and cash equivalents were $67.7M, with $109.5M including marketable securities.
- Revenue for the quarter was $250,000 from collaboration agreements.
- Net loss totaled $16.7M with EPS of -$0.39.
- R&D expense was $14.3M and G&A was $6.0M; restructuring expense was $3.4M.
- Cash, cash equivalents, and marketable securities totaled $109.5M as of June 30, 2025.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$250K
Forward guidance
Company expects initial topline data from the LIONS (RP-1664) and POLAR (RP-3467) trials in Q4 2025; continues to explore strategic alternatives and advance partnerships, including a new worldwide licensing agreement for lunresertib.
Tailwinds
- Initial data from LIONS trial expected in Q4 2025.
- Topline safety/tolerability and early efficacy data from POLAR expected in Q4 2025.
- Exclusive worldwide licensing agreement with Debiopharm for lunresertib, including upfront and milestone potential.
- Amended BMS collaboration added an additional druggable target.
- Active exploration of strategic partnerships and sale opportunities across the portfolio.
Headwinds
- No quantitative revenue or earnings guidance provided for upcoming quarters.
- Clinical milestones concentrated in Q4 2025, leaving near-term catalysts limited.
- Continuing operating and net losses highlight ongoing cash burn.
- Restructuring expenses impacted the quarter.
- Future economics from partnerships (e.g., single-digit royalties) may be modest relative to costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2025
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro